MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Key facts
- Where
- Jaú, Niterói, Porto Alegre, Ribeirão Preto, Rio de Janeiro, Salvador, São Paulo, and SP, BrazilSee the 17 sites
- Phase
- Phase 3
Where in Brazil
- Hospital Amaral CarvalhoJaú, BrazilTaking people
- Instituto Oncomed de Educação e PesquisaNiterói, BrazilTaking people
- Oncomed Clínica OncológicaNiterói, BrazilTaking people
- Centro de Pesquisa Clínica - Área AdministrativaPorto Alegre, BrazilTaking people
- Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e PesquisaPorto Alegre, BrazilTaking people
- Hospital Mae de DeusPorto Alegre, BrazilTaking people
- Hospital Moinhos de VentoPorto Alegre, BrazilTaking people
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP)Ribeirão Preto, BrazilTaking people
- Americas Centro de Oncologia IntegradoRio de Janeiro, BrazilTaking people
- Instituto de Educacao Pesquisa e Gestao em SaudeRio de Janeiro, BrazilTaking people
- Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial SalvadorSalvador, BrazilTaking people
- Clínica Médica São Germano S/S LtdaSão Paulo, BrazilTaking people
- ESHO Empresa de Serviços Hospitalares S.A/ Hospital Samaritano de HigienópolisSão Paulo, BrazilTaking people
- HU UNIFESP / SPDM - Hospital São PauloSão Paulo, BrazilTaking people
- Instituto D'Or de Pesquisa e Ensino (IDOR)São Paulo, BrazilTaking people
- Universidade Federal de Sao PauloSão Paulo, BrazilTaking people
- Clínica Médica São Germano LTDASP, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT06152575EU 2023-507871-23-00
- Record updated
- 24 August 2026
- Original description
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).Read full original descriptionShow less
A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).
This study is seeking participants who:
* Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment.
Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM.
Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study.
The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as:
* a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects.
Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits).
The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.
Inclusion: Prior diagnosis of multiple myeloma as defined by International Myeloma Working Group (IMWG) criteria and previously received 1 to 4 prior lines of therapy including prior anti-cluster of differentiation 38 (CD38) antibody and prior lenalidomide; Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria; Measurable disease defined as at least 1 of the following: (a) Serum M-protein ≥0.5 g/dL; (b) Urinary M-protein excretion ≥200 mg/24 hours; (c) Serum involved immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65); Have clinical laboratory values within the specified range; ECOG (Eastern Cooperative Oncology Group) performance status ≤2; Not pregnant or breastfeeding and willing to use contraception.
Exclusion: Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease; Any other active malignancy within 3 years prior to enrolment (exceptions include, adequately treated basal cell or squamous cell skin cancer, carcinoma in situ); Previous treatment with a B cell maturation antigen (BCMA)-directed therapy or CD3-redirecting therapy; Unable to receive investigator's choice therapy; Live attenuated vaccine within 4 weeks of the first dose of study intervention; Administration with an investigational product (e.g. drug or vaccine) within 30 days preceding the first dose of study intervention used in this study; Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities (POEMS) syndrome; Any active, uncontrolled bacterial, fungal, or viral infection; Smoldering multiple myeloma; Plasma cell leukemia; Amyloidosis; Known central nervous system (CNS) involvement or clinical signs of myelomatous meningeal involvement.